Dr. Winson Cheung, MD, MPH, FRCPC
Professor, Cumming School of Medicine, Department of Oncology
University of Calgary
Member of the Arnie Charbonneau Cancer Institute
Calgary, AB
Winson Y. Cheung, MD, MPH, FRCPC is a medical oncologist and a nationally and internationally recognized data scientist and health outcomes researcher who specializes in real-world evidence. He is currently a Full Professor of Medicine and Oncology at the University of Calgary where he is the Director of the Oncology Outcomes (O2) Research Program. Dr. Cheung received his medical degree at the University of British Columbia, medical oncology subspecialty training at the University of Toronto and subsequently obtained a Masters of Public Health degree at Harvard University.
His clinical expertise focuses on the management of gastrointestinal malignancies. He is the recipient of numerous accolades, including the National Cancer Institute of Canada Dorothy Lamont Award, the Novartis Oncology Young Canadian Investigator Mentor Award, the Multinational Association of Supportive Care in Cancer Investigator Award, and several merit awards from the American Society of Clinical Oncology. He has secured 20+ million dollars in grant funding and published over 300 peer-reviewed scientific articles.
2025 RWE O2 DAY FACULTY
Kelvin Chan
Medical Oncologist, Sunnybrook Odette Cancer Centre
Professor, University of Toronto
Associate Scientist, Sunnybrook Research Institute
Toronto, ON
Dr. Kelvin Chan is a Medical Oncologist at the Sunnybrook Odette Cancer Centre, a Professor at the University of Toronto, and an associate scientist at the Sunnybrook Research Institute. He has completed both an MSc and a PhD in Biostatistics, and also holds an MSc in Clinical Epidemiology.
Dr. Chan’s research focuses on the different aspects of the value of cancer drugs, including health economics, health technology assessment, and real-world evidence. He is the Co-Director at the Canadian Centre for Applied Research in Cancer Control (ARCC) and the Platform Director of the Canadian Cancer Real-world Evaluation (CCRE) Platform, funded the Post-Marketed Drug Evaluation (PMDE) program at the Canada’s Drug Agency.
Dr. Chan is especially interested in cancer drug reimbursement related issues. He is a member of multiple provincial and national committees related to cancer drug assessments and recommendations including the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC), the Committee to Evaluate Drugs (CED) and the Ontario Steering Committee of Cancer Drugs (OSCCD). He was also the Clinical Lead for the Provincial Drug Reimbursement Programs (PDRP) at Ontario Health – Cancer Care Ontario (OH-CCO), from September 2014 to July 2024.
Reka Pataky, PhD
Senior Health Economist, Population Health Sciences, BC Cancer
Vancouver, BC
Reka Pataky is a Senior Health Economist in the Regulatory Science Lab, led by Dr. Dean Regier at BC Cancer. She holds a PhD from the School of Population and Public Health at the University of British Columbia. Her work focuses on generating real-world evidence of effectiveness, safety, and cost-effectiveness of cancer drugs and programs using large observational datasets, to support decision-making in learning health systems.